Growth Hormone
Peptides
Compound profile

Hexarelin: Synthetic Hexapeptide GHSR Agonist

A synthetic hexapeptide ghrelin mimetic studied for GH release, with characteristic tachyphylaxis on repeated dosing.

On this page

What it is

Hexarelin is a synthetic hexapeptide GHS developed in the 1990s. Strong agonist at GHSR-1a, with secondary activity reported at the CD36 scavenger receptor.

Evidence snapshot

Category: Growth Hormone. Status: Preclinical. See the references section below for the underlying primary sources.

Mechanism

Activates GHSR-1a to produce GH release. The CD36 activity produces cardioprotective signalling in some preclinical models. Repeated dosing produces rapid tachyphylaxis.

Key research findings

Produces robust GH release in rodents and humans, with greater peak than GHRP-6. Cardioprotective effects in ischemic and pressure-overload heart failure models.

Limits of the evidence

Tachyphylaxis limits therapeutic utility. Most published clinical work was small Phase 1 pharmacokinetic studies; clinical efficacy was never established.

Continue reading

Tissue Repair

BPC-157

Synthetic pentadecapeptide derived from a gastric juice protein, studied across hundreds of preclinical reports for tissue regeneration and cytoprotection.
Read Guid
Tissue Repair

TB-500 (Thymosin Beta-4 fragment)

Synthetic fragment of Thymosin Beta-4, a 43-amino-acid peptide investigated for its role in actin regulation, cell migration, and wound healing.
Read Guid
Peptide Protocols

BPC-157 + TB-500

Combined tissue-repair peptides with complementary mechanisms — the synergy hypothesis examined critically against the available preclinical record.
Read Guid
Growth Hormone · Research

Ipamorelin

Selective pentapeptide agonist of the growth hormone secretagogue receptor (GHSR-1a) studied for targeted GH release with minimal effect on cortisol, ACTH and prolactin.
Read Guid